Get the latest on COVID-19 vaccines and treatments:
- Moderna to cut deliveries to Canada in new blow to vaccination campaign.
- Johnson & Johnson single-shot COVID-19 vaccine appears 66% effective overall in global trial.
- How countries including Canada are trying to squeeze more COVID-19 vaccine from Pfizer-BioNTech vials.
- Treatments for COVID-19: What works, doesn’t work, and is still being tested.
Regulators authorized AstraZeneca-Oxford’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population.
The European Medicines Agency’s expert committee unanimously recommended the vaccine to be used in people 18 and over, though concerns had been raised this week that not enough data exist to prove it works in older people, and some countries indicated they may not give it to the elderly.
The shot is the third COVID-19 vaccine given the green light by the European Medicines Agency (EMA) after ones by Pfizer-BioNTech and Moderna. The EMA’s decision requires final approval from the European Commission, a process that occurred swiftly with the other vaccines.
Hours later, the EU gave its backing for the vaccine’s use throughout its 27 nations.
“I expect the company to deliver the 400 million doses as agreed. We will keep on doing all we can to secure vaccines for Europeans, our neighbours & partners worldwide,” tweeted EU Commission President Ursula von der Leyen.
With trials showing about 60 per cent efficacy, the vaccine appears to offer less protection than ones already authorized, but experts have said any vaccine with an efficacy rate of over 50 per cent could help stop outbreaks.
The agency recommended the vaccine’s use in older people, despite limited data regarding its efficacy in people over 55, citing the immune responses seen and experience with other vaccines.
“At least some protection is expected,” Bruno Sepodes, of the EMA’s expert committee, said Friday at a news briefing. He acknowledged that “the exact level of protection cannot be estimated for the time being.”
Many countries on the continent have been struggling to vaccinate people as quickly as Britain, Israel, the U.S. and elsewhere, and it was long hoped that the AstraZeneca shot would help speed things up at a time when countries face surging cases in a pandemic that has taken the lives of more than 400,000 people in the 27-nation bloc.
Canada has an agreement with AstraZeneca for 20 million doses, though the vaccine is still awaiting approval from Health Canada.
The Canadian regulator said it is “currently completing its review of the submitted data and expects to make a decision on the authorization of the AstraZeneca vaccine in the coming days,” in a release on Friday responding to the EMA’s authorization.
“While the Department collaborates with other regulators, it remains committed to conducting an independent and thorough scientific review of all COVID-19 vaccines.”
Cheaper, easier to handle
The EU bet heavily on the shot, which is cheaper and easier to handle than some other vaccines, with orders for 300 million doses to be delivered after authorization and options for another 100 million doses.
“None of them is a magic wand on its own, but together they provide tools and options to prevent different aspects of the disease,” said Emer Cooke, the head of the EMA.
The AstraZeneca vaccine has been authorized for use in all adults in other countries, even though only 12 per cent of the participants in its research were over 55 and they were enrolled later, so there hasn’t been enough time to get results.
The EMA’s decision authorizes AstraZeneca’s vaccine to be used across the bloc, but individual countries can still decide how and to whom they will give the doses they receive.
Lithuania, for instance, will not use the vaccine in older people, the country’s deputy Health Minister Zivile Simonaityte said, according to the Baltic News Service. It was not clear, however, what age groups would be given the shot, but Simonaityte noted that trials in people 55 and over were not “comprehensive.”
Germany has indicated it could follow a similar path. The country’s independent vaccine advisory committee recommended Friday that the shot only be given to people under 65. The committee, known by its German acronym STIKO, said that “there currently isn’t sufficient data to assess the vaccine effectiveness from the age of 65.” The final decision rests with the government, but they are likely to follow this advice.
Cooke, EMA’s executive director, declined to say whether the regulator saw a problem with such an approach.
Julian Tang, a virologist at the University of Leicester, said the German decision to restrict the vaccine’s use to younger people meant more older people would be vulnerable to COVID-19 and that some would die unnecessarily.
“There’s a tremendous cost to this,” he said. “It means you have an extra vaccine that could be used to protect people that is going unused and more people will be at risk.”
Tang described the EMA’s authorization Friday as “the best decision in the current situation, where the EU is in desperate need of a usable vaccine.”
U.S. study still underway
The agency assessed four trials in the U.K., Brazil and South Africa and said the research showed the vaccine proved to be about 60 per cent effective by reducing the number of people who got sick. The trials have not yet shown whether the vaccine can stop disease transmission.
A separate study testing the AstraZeneca vaccine in the U.S. is still underway.
Professor Andrew Pollard, director of the Oxford Vaccine Group that developed the shot together with AstraZeneca, welcomed the decision.
“The recommendation by the European Medicines Agency is an important milestone in extending access to the Oxford/AstraZeneca vaccine in our region and providing further endorsement that, after the rigorous scrutiny of regulators, the vaccine can be used to help protect populations from the coronavirus pandemic,” he said in a statement.
As the EU has struggled to roll out the vaccine, politicians have blamed supply problems, but other factors, like onerous paperwork and poor planning, have also played a role.
The EU has particularly lashed out at AstraZeneca after the drugmaker said it would initially supply less vaccine than originally anticipated.
Exacerbating concerns about supplies to the bloc, which is home to some 450 million people, Moderna told countries including Italy and Denmark the company would be delivering fewer vaccines than originally expected.
German Health Minister Jens Spahn said Friday he understood many were waiting impatiently for the vaccine, but cautioned that “several hard weeks of vaccine shortage still lie before us.”
More results announced
Two more vaccine makers also recently announced results, with Novavax saying this week that its shot appears 89 per cent effective based on early findings, and Johnson & Johnson saying its long-awaited single-shot vaccine was 66 per cent effective at preventing moderate to severe illness.
If those vaccines are eventually licensed, that could help alleviate the pressure on the world’s huge demand for the limited shots currently available.
Virologist Eric Arts at Western University in London, Ont., welcomed the news from AstraZeneca, Novavax and Johnson & Johnson.
“I think Canadians should be very happy by what’s emerged,” Arts said.
He noted that greater diversity in vaccines that are produced in slightly different ways means avoiding competing for the same resources and materials.
“This shortens the timeline to get our population vaccinated and so I think we should all take solace in that,” said Arts, who holds the Canada Research Chair in HIV Pathogenesis and Viral Control.
The authorization of the AstraZeneca vaccine comes amid a bitter dispute between the drugmaker and the bloc after the company said it would sharply reduce initial deliveries from 80 million doses to 31 million.
The EU also introduced tighter rules on exports of COVID-19 vaccines that could hit shipments to nations like the United Kingdom.
Credits belong to : www.cbc.ca